Treating Co-Occurring Substance Use and Mental Disorders Among Jail Inmates
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
North Carolina
-
Research Triangle Park, North Carolina, United States, 27709
- RTI International
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- (1) drug or alcohol abuse or dependence and SMI (major depressive disorder; depressive disorder not otherwise specified [NOS]; bipolar disorder I, II, or NOS; schizophrenia spectrum disorder; schizoaffective disorder; schizophreniform disorder; brief psychotic disorder; delusional disorder; or psychotic disorder NOS);
- (2) resident of Wake County and detained in The Jail;
- (3) >18 years of age; (4) able to speak/read English; and (5) able to provide informed consent.
Exclusion Criteria:
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: DDMI-IGT
Subjects randomized to the experimental condition will receive adapted versions of dual-diagnosis motivational interviewing ([DDMI] one session before release from jail) and integrated group therapy ([IGT] 12 community-based sessions over a 2-month period).
|
DDMI is an evidence-based adaptation to motivational interviewing.
DDMI incorporates an integrated framework and accommodates cognitive impairments and disordered thinking associated with co-occurring substance use and mental disorders.
IGT is an evidence-based practice for treating co-occurring disorders.
IGT focuses on relapse prevention by reducing substance use and stabilizing psychiatric symptoms.
|
|
Active Comparator: Usual care
Subjects randomized to the usual care condition will receive jail and community-based behavioral health services.
|
Existing behavioral health service programs
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acceptability
Time Frame: Study months 21 through 34
|
Client Satisfaction Questionnaire-8, Narrative Evaluation of Intervention Interview
|
Study months 21 through 34
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility of Adapted Interventions
Time Frame: Study months 21 through 34
|
How successfully can the adapted interventions be implemented (Focus Group interviews)
|
Study months 21 through 34
|
|
Fidelity
Time Frame: Study months 21 through 34
|
DDMI and IGT Adherence Forms
|
Study months 21 through 34
|
|
Substance use
Time Frame: Study months 20 through 30
|
Addiction Severity Index
|
Study months 20 through 30
|
|
Psychiatric symptoms
Time Frame: Study months 20 through 30
|
Brief Psychiatric Rating Scale
|
Study months 20 through 30
|
|
Health status
Time Frame: Study months 20 through 30
|
SF-12
|
Study months 20 through 30
|
|
Service use
Time Frame: Study months 20 through 30
|
Epidemiological Catchment Area Interview
|
Study months 20 through 30
|
|
Externalizing behaviors
Time Frame: Study months 20 through 30
|
Triarchic Psychopathy Measure
|
Study months 20 through 30
|
|
Quality of life measure
Time Frame: Study months 20 through 30
|
Heinrichs-Carpenter Quality of Life Scale, Plus
|
Study months 20 through 30
|
|
Arrest
Time Frame: Study months 20 through 30
|
Self-report and official jail records
|
Study months 20 through 30
|
|
Treatment preferences
Time Frame: Study months 20 through 30
|
Visual analog ranking of 8 different aspects of treatment
|
Study months 20 through 30
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Richard A Van Dorn, Ph.D., RTI International
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- R34DA036791 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.